Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib Combined With Famitinib or SHR-1701 for Neoadjuvant Therapy in Advanced Ovarian Cancer
NCT07355010Phase 2Not yet recruiting
- Start
- Dec 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of fluzoparib in ovarian cancer. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
fluzoparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT07355010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07355010.